EICHORPublic-registry site landscape for NCT03381170, “An Extension of the TG1101-RMS201 Trial”, a Relapsing Remitting Multiple Sclerosis study sponsored by TG Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03381170 (registry record) |
| Study title | An Extension of the TG1101-RMS201 Trial |
| Official title | An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis |
| Sponsor | TG Therapeutics, Inc. |
| Condition(s) | Relapsing Remitting Multiple Sclerosis |
| Phase | PHASE2 |
| Listed sites | 8 |
| Intervention(s) | Ublituximab |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03381170.
Eichor generates a preliminary site-risk snapshot for NCT03381170 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Relapsing Remitting Multiple Sclerosis trials
More from TG Therapeutics, Inc.
← Eichor home · All tracked trials · Relapsing Remitting Multiple Sclerosis studies · Weekly briefs
